Immunotherapeutics to Treat HIV in the Central Nervous System.
Broadly neutralizing antibodies
CAR-T cell therapy
Central nervous system
HIV-1
Immunotherapy
Therapeutic HIV-1 vaccine
Journal
Current HIV/AIDS reports
ISSN: 1548-3576
Titre abrégé: Curr HIV/AIDS Rep
Pays: United States
ID NLM: 101235661
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
pubmed:
17
7
2020
medline:
17
2
2021
entrez:
17
7
2020
Statut:
ppublish
Résumé
The application of immunotherapies to HIV presents a new horizon of treatment options, but little is known about what impact they may have on the central nervous system (CNS). Here we review the most promising immunotherapeutic strategies that can be used to target HIV in the CNS and focus on identifying their potential benefits while exploring the challenges that remain in their application. We have identified five immunotherapeutic strategies that hold potential in managing CNS disease among HIV-infected patients. These include broadly neutralizing antibodies, multi-affinity antibodies, CAR-T cell therapy, checkpoint inhibitors, and therapeutic vaccines. Each class of immunotherapy presents unique mechanisms by which CNS viremia and latency may be addressed but are faced with several challenges. CAR-T cell therapy and multi-affinity antibodies seem to hold promise, but combination therapy is likely to be most effective. However, more human trials are needed before the clinical benefits of these therapies are realized.
Identifiants
pubmed: 32671567
doi: 10.1007/s11904-020-00519-w
pii: 10.1007/s11904-020-00519-w
pmc: PMC7492473
mid: NIHMS1612396
doi:
Substances chimiques
Antibodies, Neutralizing
0
HIV Antibodies
0
Immune Checkpoint Inhibitors
0
Viral Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
499-506Subventions
Organisme : NIMH NIH HHS
ID : R21 MH112360
Pays : United States
Organisme : NIMH NIH HHS
ID : R33 MH112360
Pays : United States
Références
Curr Opin HIV AIDS. 2018 Sep;13(5):446-453
pubmed: 29878913
Annu Rev Med. 2018 Jan 29;69:421-436
pubmed: 29099677
Curr HIV/AIDS Rep. 2012 Mar;9(1):81-90
pubmed: 22198819
Curr Opin HIV AIDS. 2018 Jul;13(4):366-373
pubmed: 29697469
J Leukoc Biol. 2019 Jun;105(6):1253-1259
pubmed: 30730588
CNS Drugs. 2018 Dec;32(12):1091-1101
pubmed: 30387077
Expert Rev Clin Immunol. 2016;12(2):91-4
pubmed: 26629806
Sci Transl Med. 2012 May 2;4(132):132ra53
pubmed: 22553251
Curr Opin HIV AIDS. 2014 Nov;9(6):552-8
pubmed: 25203642
J Neurovirol. 2015 Jun;21(3):276-89
pubmed: 25236812
J Intern Med. 2009 Jan;265(1):125-37
pubmed: 19093965
N Engl J Med. 2019 Apr 25;380(17):1597-1605
pubmed: 30969503
J Clin Invest. 2019 Jul 15;129(8):3339-3346
pubmed: 31305262
Nat Rev Drug Discov. 2017 Oct 30;16(11):754
pubmed: 29081527
Curr HIV/AIDS Rep. 2011 Mar;8(1):54-61
pubmed: 21191673
J Immunother Cancer. 2019 May 22;7(1):134
pubmed: 31118078
Retrovirology. 2018 Aug 29;15(1):60
pubmed: 30157871
Nat Med. 2016 Apr;22(4):362-8
pubmed: 26998834
J Virol. 2018 Aug 29;92(18):
pubmed: 29976677
Eur J Cancer. 2017 Mar;73:1-8
pubmed: 28064139
Front Immunol. 2016 Sep 30;7:397
pubmed: 27746784
Annu Rev Med. 2018 Jan 29;69:409-419
pubmed: 29029583
Nature. 2015 Jun 25;522(7557):487-91
pubmed: 25855300
N Engl J Med. 2018 Aug 16;379(7):645-654
pubmed: 30110589
Expert Rev Anti Infect Ther. 2017 Aug;15(8):747-758
pubmed: 28692305
Sci Transl Med. 2014 Nov 5;6(261):261ra154
pubmed: 25378646
J Natl Cancer Inst. 2019 Jul 1;111(7):646-654
pubmed: 30753567
Front Immunol. 2019 Oct 04;10:2267
pubmed: 31636630
Clin Infect Dis. 2006 Aug 15;43(4):500-11
pubmed: 16838241
Curr Opin Virol. 2019 Oct;38:21-30
pubmed: 31132749
Nature. 2013 Nov 14;503(7475):224-8
pubmed: 24172905
Curr HIV/AIDS Rep. 2018 Apr;15(2):147-154
pubmed: 29500712
AIDS Res Hum Retroviruses. 2018 Sep;34(9):739-759
pubmed: 30056745
J Virus Erad. 2015 Apr;1(2):67-71
pubmed: 26430703
Nat Commun. 2019 Jul 2;10(1):2753
pubmed: 31266936
Neurology. 2014 Jul 8;83(2):134-41
pubmed: 24907236
Infect Disord Drug Targets. 2011 Apr;11(2):167-74
pubmed: 21406048
AIDS. 2015 Feb 20;29(4):504-6
pubmed: 25628259
Pharmacotherapy. 2015 Oct;35(10):963-76
pubmed: 26497482
Nat Commun. 2018 Feb 28;9(1):877
pubmed: 29491415
Curr Opin HIV AIDS. 2013 May;8(3):165-9
pubmed: 23429501
Front Immunol. 2019 Sep 10;10:2109
pubmed: 31552045
Science. 2008 May 9;320(5877):760-4
pubmed: 18467582
Mol Ther Oncolytics. 2016 Apr 20;3:16011
pubmed: 27626062
PLoS One. 2013 Oct 21;8(10):e77780
pubmed: 24204962
Blood. 2003 Jan 15;101(2):466-8
pubmed: 12393404
Curr HIV/AIDS Rep. 2019 Feb;16(1):96-104
pubmed: 30734905
Nature. 2009 Mar 12;458(7235):206-10
pubmed: 19078956
Curr Opin Virol. 2019 Oct;38:70-80
pubmed: 31421319
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
Immunol Rev. 2017 Jan;275(1):285-295
pubmed: 28133801
Curr Opin HIV AIDS. 2018 Sep;13(5):408-415
pubmed: 29957615
J Immunol. 2007 Jun 1;178(11):6975-83
pubmed: 17513747
Ann Oncol. 2018 Feb 1;29(2):517-518
pubmed: 29206889
Cell Host Microbe. 2018 Jul 11;24(1):25-33
pubmed: 30001521
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
Immunotherapy. 2017 Mar;9(5):401-410
pubmed: 28357916
J Cereb Blood Flow Metab. 2013 Jan;33(1):13-21
pubmed: 23072749
J Antimicrob Chemother. 2012 Feb;67(2):299-311
pubmed: 22160207
J Clin Invest. 2016 Feb;126(2):455-63
pubmed: 26731469
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
AIDS Res Hum Retroviruses. 2005 May;21(5):363-70
pubmed: 15929698
Nat Med. 2018 Nov;24(11):1701-1707
pubmed: 30258217
Science. 2017 Oct 6;358(6359):85-90
pubmed: 28931639
Arch Neurol. 2008 Jan;65(1):65-70
pubmed: 18195140
Sci Transl Med. 2019 Aug 7;11(504):
pubmed: 31391322
J Clin Invest. 2016 Feb;126(2):415-23
pubmed: 26752643
N Engl J Med. 2018 Jan 18;378(3):295-297
pubmed: 29342376
Clin Infect Dis. 2010 Mar 1;50(5):773-8
pubmed: 20100092
Nat Immunol. 2015 Jun;16(6):584-9
pubmed: 25990814
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11478-83
pubmed: 9326635
Curr Opin HIV AIDS. 2016 Nov;11(6):607-613
pubmed: 27537673